Effect of ramosetron on QTc interval: A randomised controlled trial in patients undergoing off-pump coronary artery bypass surgery

Ramosetron is a relatively new 5-hydroxytryptamine three receptor antagonist with higher binding affinity and more prolonged duration of action compared to ondansetron. The present study was performed to evaluate the effects of ramosetron on QTc interval and possible cardiovascular adverse effects in patients undergoing cardiac surgery.